摘要
采用酶联免疫法测定了初诊2型糖尿病患者、糖调节受损（IGR）患者、正常糖耐量（NGT）者血浆nesfatin-1水平。结果显示，2型糖尿病和IGR组血浆nesfatin-1水平明显高于NGT组[（1．91±0．79和1．80~0．80对1．41±0．58）μg/L，P〈0．01]。血浆nesfatin-1水平与体重指数（BMI）、空腹血糖、空腹胰岛素、HbA。稳态模型评估的胰岛素抵抗指数（HOMA-IR）呈明显正相关（P〈0．05或P〈0．01）。多元回归分析结果表明HOMA．IR和BMl分别是影响血浆nesfatin-1水平的独立相关因素（均P〈0．01）。提示血浆nesfatin-1可能参与了胰岛素抵抗和2型糖尿病的发生和发展。
[Summary] Plasma nesfatin-1 levels were assayed by ELISA in patients with impaired glucose regulation （IGR）, type 2 diabetes mellitus （T2DM）, and healthy subjects with normal glucose tolerance （control group）. The results showed that plasma nesfatin-1 levels in IGR and T2DM groups were significantly higher than that in control group [ （ 1.91 ±0. 79 and 1.80±0. 80 vs 1.41±0. 58 ） μg/L, P〈0. 01 ]. Plasma nesfatin-1 levels were positively correlated with body mass index （BMI）, HbA1c, waist hip ratio, fasting plasma glucose, fasting insulin, and homoestasis model assessment insulin resistant index（ HOMA-IR, P〈0. 05 or P〈0. 01 ）. Multiple regression analysis showed that BMI and HOMA-IR were independent related factors in influencing plasma nesfatin-1 levels （ both P〈0.01 ）. These results suggest that nesfatin-1 may partially contribute to the pathogenesis of insulin resistance and T2DM.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2012年第1期26-28,共3页
Chinese Journal of Endocrinology and Metabolism
基金
国家自然科学基金项目（30771037、30871199、30971388、81070640）
